Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer (mCRC).
Heinz-Josef J. Lenz, et al.
取材予定演題リスト
※本リストに掲載の演題は、発表前の限られた情報をもとに取材候補として選んだものです。
諸事情により、予告なく取材・掲載を取り止める場合がありますので、あらかじめご了承ください。
Proffered Paper Session
Abstract #LBA18_PR
Abstract #LBA19
Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL ? a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
Axel Grothey, et al.
Abstract #LBA20
TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts).
Chiara Cremolini, et al.
Abstract #LBA25
TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer.
Hendrik-Tobias Arkenau, et al.
Abstract #LBA26
Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC).
Michael J. Pishvaian, et al.
Abstract #LBA27
A Randomized Multicentered Phase 2 Study to Evaluate SHR-1210 (PD-1 Antibody) in Subjects with Advanced Hepatocellular Carcinoma (HCC) who Failed or Intolerable to Prior Systemic Treatment.
Shu-Kui Qin, et al.
Abstract #50O
Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the Circulating Cell-Free Genome Atlas (CCGA) study.
Minetta C. Liu, et al.
Abstract #615O
Randomized phase III study of Gemcitabine, Cisplatin plus S-1 (GCS) versus Gemcitabine, Cisplatin (GC) for Advanced Biliary Tract Cancer (KHBO1401-MITSUBA).
Daisuke Sakai, et al.
Poster Discussion Session
Abstract #LBA28
Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.
Milind Javle, et al.
Abstract #453PD
1st-line mFOLFOXIRI + Panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: a randomized phase II VOLFI trial of the AIO (KRK-0109).
Michael Geissler, et al.
Abstract #454PD
Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer.
Hiroya Taniguchi, et al.
Abstract #617PD
A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.
Taroh Satoh, et al.
Abstract #620PD
Influence of enteral nutrition on nutritional status, treatment toxicities, and short-term outcomes in esophageal carcinoma patients treated with concurrent chemoradiotherapy: a prospective, multicenter, randomized controlled study.
Tao Li, et al.
Poster Display Session
Abstract #467P
Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer.
Toshiki Masuishi, et al.
Abstract #563P
Updated results of phase 1 study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer.
Takayuki Yoshino, et al.
Abstract #667P
A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX).
Keisho Chin, et al.
Abstract #668P
Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B.
Satoshi Yuki, et al.